908 Devices Inc. — Q3 2023 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2023. Unaudited results are compared with the corresponding 2022 periods. 908 Devices develops handheld and desktop instruments for point-of-need chemical and biochemical analysis.
Financial performance
Amounts below are in millions, except per-share data and percentages.
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $14.3 | $15.8 | $35.9 | $35.2 |
| Gross profit | $7.9 | $9.3 | $18.0 | $20.1 |
| Gross margin | 55.0% | 59.1% | 50.3% | 57.1% |
| Operating loss | $(9.1) | $(7.2) | $(33.0) | $(25.0) |
| Net loss | $(7.1) | $(6.3) | $(29.0) | $(23.8) |
| Basic and diluted loss per share | $(0.22) | $(0.20) | $(0.90) | $(0.76) |
- Revenue mix and changes: Q3 revenue declined 9.5% year over year, primarily as desktop device sales and contract revenue fell; service revenue increased. For the first nine months, revenue rose 1.9%: service revenue grew 37% to $6.7 million, while product revenue was nearly flat at $28.8 million and contract revenue fell 67% to $0.4 million.
- Products and margins: Nine-month product gross margin fell to 54% from 61%, which management attributed mainly to unfavorable product mix, higher materials and warranty/production costs, inventory obsolescence provisions, and additional intangible amortization. Q3 service gross margin fell to 17% from 40%, reflecting higher servicing materials, contract trainers and personnel costs.
- Expenses and earnings: Nine-month operating expenses rose 13% to $51.1 million. R&D increased 28% to $16.5 million; SG&A increased 7% to $34.6 million. Higher interest income partially offset increased operating losses.
- Cash flow: Operating cash use was $23.1 million for the first nine months, versus $15.8 million in 2022. Investing cash use was $31.0 million, including net purchases of marketable securities; financing cash use was $16.0 million, mainly repayment of $15.0 million of revolver borrowings and contingent-consideration payments. Cash, cash equivalents and restricted cash decreased $70.2 million to $118.4 million.
- Liquidity and debt: At September 30, cash and cash equivalents were $118.2 million and marketable securities were $29.7 million, or $147.9 million combined. Current assets were $179.8 million and current liabilities $22.3 million. No revolver balance or long-term debt was outstanding. The amended credit facility provides up to $10 million through November 2025 and requires, among other covenants, $20 million to be maintained at or through SVB and a minimum-cash measure tied to cash burn.
Management outlook, risks and unusual items
- Management expects continued operating losses while investing in commercial expansion, manufacturing capacity and product development. It believes available cash, cash equivalents and marketable securities, together with product and service revenue, will fund operating expenses, capital expenditures and debt service for at least 12 months from issuance of the financial statements; this estimate depends on assumptions that may prove incorrect.
- No specific revenue, earnings or margin guidance is provided. Management expects recurring revenue to increase as the installed base grows, while noting that device sales and customer purchasing patterns can fluctuate considerably.
- Risks highlighted include customer spending pressure from inflation, interest rates and constrained financing; lengthy and variable sales cycles; reliance on a small number of customers and limited-source suppliers; competition and product-adoption uncertainty; and the need for additional financing if operating needs exceed available resources. Two customers represented 41% and 17% of Q3 revenue; one customer represented 47% of gross receivables at quarter-end.
- Following SVB’s closure and the company’s transfer of deposits, the company reported a covenant default under its former facility and a $0.5 million debt-extinguishment loss in Q1. An August amendment reduced the revolver commitment from $35 million to $10 million and waived specified remedies. The Trace acquisition also generated contingent consideration; remaining fair value was $0.7 million at quarter-end.
- The company reported no material legal proceedings or material changes to the risk factors in its 2022 Form 10-K. Management concluded disclosure controls were effective at a reasonable assurance level.
Important facts for investors to verify
- Whether revenue growth, particularly desktop placements and recurring consumables and service sales, supports improved gross margins; Q3 handheld placements were 117 versus 150, and desktop placements were 7 versus 25.
- Whether operating cash use and the $147.9 million cash-and-securities balance remain consistent with management’s stated minimum 12-month runway.
- Compliance with the amended SVB facility’s $20 million deposit covenant and minimum-cash covenant, and the practical availability of the $10 million revolver.
- Customer concentration, receivable collection, and exposure to sole- or limited-source component suppliers.
- Progress integrating Trace technology and the timing or amount of remaining earnout payments; the filing text does not provide a clear quantified outlook for future revenue or profitability.